AstraZeneca PLC (LON:AZN) Announces Dividend of GBX 156

AstraZeneca PLC (LON:AZNGet Free Report) announced a dividend on Thursday, February 8th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, February 22nd will be given a dividend of GBX 156 ($1.96) per share by the biopharmaceutical company on Monday, March 25th. This represents a yield of 1.49%. The ex-dividend date is Thursday, February 22nd. This is a positive change from AstraZeneca’s previous dividend of $71.80. The official announcement can be accessed at this link.

AstraZeneca Trading Up 0.8 %

Shares of AZN stock opened at GBX 9,901.36 ($124.12) on Friday. AstraZeneca has a 12-month low of GBX 9,700 ($121.60) and a 12-month high of £123.92 ($155.35). The firm’s 50 day moving average is £104.80 and its 200 day moving average is £105.98. The company has a current ratio of 0.79, a quick ratio of 0.59 and a debt-to-equity ratio of 79.40. The stock has a market capitalization of £153.47 billion, a P/E ratio of 3,307.41, a P/E/G ratio of 0.51 and a beta of 0.16.

Insider Activity

In other AstraZeneca news, insider Anna Manz bought 487 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were purchased at an average price of £101.90 ($127.74) per share, with a total value of £49,625.30 ($62,210.48). In other AstraZeneca news, insider Michel Demare purchased 1,000 shares of AstraZeneca stock in a transaction dated Wednesday, November 22nd. The stock was acquired at an average price of £101.70 ($127.49) per share, for a total transaction of £101,700 ($127,491.54). Also, insider Anna Manz acquired 487 shares of AstraZeneca stock in a transaction that occurred on Tuesday, December 12th. The stock was acquired at an average cost of £101.90 ($127.74) per share, with a total value of £49,625.30 ($62,210.48). Corporate insiders own 0.21% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on AZN shares. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Friday, November 17th. Jefferies Financial Group reduced their price objective on shares of AstraZeneca from £130 ($162.97) to £125 ($156.70) and set a “buy” rating for the company in a research note on Monday, November 27th. Barclays reissued a “buy” rating and set a £135 ($169.24) price target on shares of AstraZeneca in a report on Monday, November 20th. Finally, Berenberg Bank reissued a “buy” rating and set a £125 ($156.70) target price on shares of AstraZeneca in a research note on Tuesday, November 21st. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of £118.95 ($149.12).

Get Our Latest Research Report on AZN

About AstraZeneca

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

See Also

Dividend History for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.